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with metastatic or advanced hepatocellular carcinoma
(HCC) that cannot be treated by loco-regional therapy.
However, its objective response rate is only 2e3% and the
median time-to-progression is around 2.8 months in the
Asian population.1 Other anti-angiogenic agents, such as
bevacizumab, have been reported to have similar efficacy.2
The long-term disease-free or cure of advanced HCC by
anti-angiogenic therapy alone is extremely rare.
A 24-year-oldwomanwith no history of chronic hepatitis B
or C virus infection was diagnosed with HCC in June 2005 by
liver tumor biopsy. Computed tomography scans revealed
multiple large intra-hepatic tumors extending into the
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http://dx.doi.org/10.1016/j.jfma.2012.07.036(Fig. 1B). Serum alpha-fetoprotein (AFP) level exceeded
87,500 ng/mL. She was enrolled into a Phase II clinical trial
using bevacizumab (7.5 mg/kg, on day 1, triweekly) and
capecitabine (800mg/m2, twice daily, days 1e14, triweekly)
as the first-line therapy.3 Partial response was achieved
(Fig. 1C), and all the metastatic lung tumors disappeared
(Fig. 1D). She was treated with the same regimen for a total
of 2 years, and the disease was controlled in partial response
status. The lowest AFP level was 76,636 ng/mL.
However, a follow-up computed tomography scan in
April 2007 revealed spleen metastasis. Positron emission
tomography with 18-fluorodeoxyglucose confirmed the
involvement of liver and spleen, but not the lungs. Due to
her young age, good performance status and there being no
proven effective therapy at that time, right hepatectomy,
segmentectomy of the second hepatic segment and sple-
nectomy were performed in June 2007. Pathology reports
showed a Grade III HCC with clear resection margins. Serum
AFP level normalized afterwards. The patient then received
regular follow-up by imaging exams every 3 months. In June
2012, 7 years after the diagnosis of advanced HCC and 5& Formosan Medical Association. All rights reserved.
Figure 1 Computed tomography scan showing the patient’s disease at diagnosis (A, B) and after anti-angiogenic therapy
achieving partial response (C, D).
578 Y.-Y. Shao et al.years after the surgery, she remained disease-free and her
serum AFP level remained normal.
A few case reports have previously described how good
outcomes can be achieved with aggressive surgery of
metastatic disease.4,5 However, these reported cases had
either limited or solitary metastasis. Our patient had very
extensive disease involvement at diagnosis, so direct
surgery was not feasible. To our best knowledge, this is the
first reported case describing how an effective systemic
therapy converted an initially metastatic and unresectable
HCC to resectable status.
A previous case report demonstrated that a complete
pathological response was achieved in a locally-advanced
HCC patient treated with sorafenib.6 Our current case
demonstration, together with prior case reports, indicates
that although advanced HCC is notoriously refractory to
most systemic treatment and rapid in progression, multi-
modality treatment in carefully selected patients might
lead to a surprisingly good outcome.
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